Nanostics
Canadian precision-diagnostics company developing minimally invasive, machine-learning–based blood tests for disease risk assessment. Operates an accredited clinical laboratory and publishes peer-reviewed validation studies. Primary clinical offering is an adjunctive blood-based prostate cancer risk assessment that integrates extracellular vesicle and PSA measurements with clinical features to inform biopsy and imaging decisions. The organisation conducts multi-site clinical validation, maintains regional specimen collection partnerships, and pursues regulatory approvals and commercial partnerships for broader deployment.
Industries
Nr. of Employees
small (1-50)
Products
Adjunctive blood-based prostate cancer risk assessment (commercial)
Commercial blood-based diagnostic that combines biomarker measurements (including PSA and extracellular vesicle features) with clinical inputs using machine-learning models to estimate probability of clinically significant prostate cancer and inform biopsy and MRI decisions.
Adjunctive blood-based prostate cancer risk assessment (commercial)
Commercial blood-based diagnostic that combines biomarker measurements (including PSA and extracellular vesicle features) with clinical inputs using machine-learning models to estimate probability of clinically significant prostate cancer and inform biopsy and MRI decisions.
Services
Provision of accredited laboratory testing for PSA and related assays with integrated machine-learning risk scoring and secure electronic delivery of results to requesting healthcare providers to support biopsy and imaging decisions.
Provision of accredited laboratory testing for PSA and related assays with integrated machine-learning risk scoring and secure electronic delivery of results to requesting healthcare providers to support biopsy and imaging decisions.
Expertise Areas
- Machine learning for diagnostic risk prediction
- Liquid biopsy and extracellular vesicle analysis
- Clinical validation and multi-site study management
- Accredited clinical laboratory operations and clinical assay deployment
Key Technologies
- Machine-learning risk models
- Microflow / small-particle flow cytometry
- Extracellular vesicle (EV) fingerprinting
- Total and free PSA immunoassays
News & Updates
Moderated poster presented at CUA 2026: 'Understanding urologists’ perspectives on using an AI-enabled decision support tool in healthcare.'
Attendance and exhibition at industry and public events to engage stakeholders on prostate cancer screening and diagnostic workflows.
Publication reporting development and multi-site validation of machine-learning models predicting clinically significant prostate cancer with and without optional clinical inputs (DRE, MRI), including reported AUC and sensitivity values.
Announcement of CE‑IVD marking for the prostate cancer blood test enabling distribution in the European Economic Area.
Funding award to support broader adoption and integration of the prostate cancer diagnostic across Canadian healthcare settings.
Announcement that a procedural/PLA code was granted to support clinical use and billing workflows in the United States.
Moderated poster presented at CUA 2026: 'Understanding urologists’ perspectives on using an AI-enabled decision support tool in healthcare.'
Attendance and exhibition at industry and public events to engage stakeholders on prostate cancer screening and diagnostic workflows.
Publication reporting development and multi-site validation of machine-learning models predicting clinically significant prostate cancer with and without optional clinical inputs (DRE, MRI), including reported AUC and sensitivity values.
Announcement of CE‑IVD marking for the prostate cancer blood test enabling distribution in the European Economic Area.
Funding award to support broader adoption and integration of the prostate cancer diagnostic across Canadian healthcare settings.
Announcement that a procedural/PLA code was granted to support clinical use and billing workflows in the United States.